Sign up


Match Document Document Title
8722042 Use of ventricular enlargement rate in intravenous immunoglobulin treatment of alzheimer's disease  
The present invention relates to the use of MRI monitoring of ventricular enlargement rate as an objective measure for the purpose of assessing disease progression in patients suffering from...
8722041 Anti-human equilibrative nucleoside transporter 1 (hENT1) antibodies and methods of use thereof  
This invention provides monoclonal antibodies that recognize hENT1. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and/or prophylactic in...
8722613 Methods and compositions for inhibition of nuclear factor kappaB  
A series of p105-based NF-κB super repressors, designated p-105(sr), have been designed. The p105(sr), no longer generates p50 and undergoes signal-induced degradation, effectively inhibiting all ...
8722349 Methods and kit for endometriosis screening  
Methods of screening a bodily sample for endometriosis are provided. The bodily sample is preferably saliva. According to one embodied method, the bodily sample is subjected to a denaturing...
8715620 Treatment of asthma in mammals with clostridia neurotoxins  
A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the...
8715656 Therapeutic use of specific ligand in MSRV associated diseases  
The present invention deals with a ligand comprising each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID...
8716455 Genetic products differentially expressed in tumors and use thereof  
The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and...
8715653 Modulation of Rhamm (CD168) for selective adipose tissue development  
Herein is described the methods and compositions for modulation of Rhamm, also known as CD 186, and its effects on wound repair, muscle differentiation, bone density and adipogeneisis through its...
8715652 Immunoglobulin preparations having increased stability  
The present invention relates to a protein preparation having increased stability, comprising a stabiliser selected from the group consisting of non-polar and basic amino acids and having a pH of...
8715666 Method for the potentiation of opioid analgesics effects on pain  
According to the invention there is provided use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA combined with at least one opioid analgesic for the preparation of a...
8716235 Method for inhibiting metastasis by using anti-CCL3 antibodies  
Methods and compositions are provided for inhibiting metastasis of a tumor in a subject, or of inhibiting progression of a primary tumor in a subject which requires macrophages for progression.
8715654 Methods of modulating the negative chemotaxis of immune cells  
The current invention is directed to methods of inducing migration of an immune cell toward a cancer cell comprising inhibiting the activity of a chemorepellant released from the cancer cell.
8715655 Human anti-α9 integrin antibody  
The present invention provides a human anti-α9 integrin antibody or an antibody fragment which specifically recognize human α9 integrin and mouse α9 integrin, inhibit interaction with their li...
8715658 Methods for treating conditions mediated by the inflammatory cytokine cascade using GAPDH inhibitors  
The present invention is directed to a method of treating a subject at risk for or having a condition mediated by an inflammatory cytokine cascade comprising administering to the subject an amount...
8716215 Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease  
A method of treatment for treating, preventing, inhibiting or reducing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or for restoring...
8715657 Therapeutic antibodies binding IL12Rβ1  
The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12Rβ2 chain) as well as IL23 r...
8715670 Human monoclonal antibody that specifically binds to VCAM-1 and a composition for treating an inflammatory disease or a cancer comprising the same  
The present invention relates to a human monoclonal antibody that specifically binds to VCAM-1, and a therapeutic composition for the treatment of inflammatory disease or cancer comprising the...
8715659 Single domain brain-targeting antibody fragments derived from llama antibodies  
A phage-displayed library of llama single heavy domain antibodies (sdAbs) was enriched for species that selectively bind to and are internalized by human cerebromicrovascular endothelial cells...
8715660 Treatment of angiogenesis disorders  
This invention concerns pathological angiogenesis and cancer, related treatment methods, and related compositions. Also disclosed are related diagnosis kits and methods.
8710202 Isolated nucleic acid molecule encoding an antibody that reduces GDF-8 activity  
The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also...
8709413 Treatment of celiac disease with IgA  
A process is provided for inhibiting symptoms of food allergy or food intolerance in a subject that includes the oral administration to the subject suffering from food allergy or food intolerance...
8709409 Method for treating rheumatoid arthritis by administering an anti-IL-6 antibody and methotrexate  
A pharmaceutical composition for the treatment of interleukin-6 (IL-6) related diseases, comprising an interleukin-6 antagonist (IL-6 antagonist) and immunosuppressants. The IL-6 antagonist is...
8709418 Pharmaceutical composition for treating CAPRIN-1 expressing cancer  
According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen...
8709410 ***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
Anti-prion protein antibody fragment
 
The invention relates to an antibody, antibody fragment or derivative thereof which specifically recognizes a prion protein and which comprises a complementarity determining region (CDR), a...
8709412 Modulation of TIM receptor activity in combination with cytoreductive therapy  
A genetic locus and corresponding family of proteins associated with regulation of immune function and cell survival are provided. These genes encode cell surface molecules with conserved IgV and...
8709416 Compositions of PD-1 antagonists and methods of use  
Methods of treating cancer and infectious diseases utilizing a treatment regimen comprising administering a compound that reduces inhibitory signal transduction in T cells, in combination with a...
8709417 Combination immunotherapy for the treatment of cancer  
Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-I, etc.) are demonstrated herein to be useful for the treatment of tumors.
8709414 Superagonistic anti-CD28 antibodies  
The present invention relates to one or more nucleic acid(s) encoding a binding molecule specifically binding to a human CD28 molecule, comprising (a) a nucleic acid sequence encoding a VH region...
8709415 Antibodies to OX-2/CD200 and uses thereof  
This application provides methods and compositions for modulating and/or depleting CD200 positive cells.
8709425 Antibodies to non-functional P2X7 receptor  
The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between function and non-functional P2X7 receptors, pharmaceutical compositions and kits...
8709411 Combination therapy to enhance NK cell mediated cytotoxicity  
The function of natural killer (NK) cells is regulated by inhibitory and activating signals delivered by cell surface receptors, 1-7F9 is a fully human monoclonal antibody (mAb) directed against...
8703712 Targeting cancer stem cells with DR5 agonists  
Provided is a method of determining the level of resistance or sensitivity of cancer stem cells to a death receptor agonist. The method includes detecting the level of IAP in one or more...
8703128 Methods of modulating TGFβ signaling  
The present invention provides methods of identifying the presence of or quantifying the amount of one or more of T helper (Th) cells and iTreg cells present in a sample by identifying the presence...
8703127 Methods and materials for the diagnosis of prostate cancers  
Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample...
8703130 Bispecific anti-VEGF/anti-ANG-2 antibodies  
The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses...
8703920 Fully human antibodies against N-cadherin  
The present application provides fully human antibodies against N-Cadherin for therapeutic and diagnostic methods in cancer.
8703141 Method for treating Crohn's disease by administering an anti-IL-12 antibody  
Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating...
8703138 Treatment of inflammatory diseases by inhibiting cold-inducible RNA-binding protein (CIRP)  
Disclosed are pharmaceutical compositions comprising a CIRP inhibitor. A method of treating a subject suffering from an inflammatory condition comprising administering to said subject a CIRP...
8703129 Antibodies against extended type 1 chain antigens, derivatives thereof and use  
Disclosed herein are antibodies or antigen-binding portions thereof directed against extended Type I chain antigens, in particular extended Type I chain glycosphingolipids, and the uses of the...
8703126 Reduced-viscosity concentrated protein formulations  
The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method...
8703124 Combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system  
The present application provides a pharmaceutical composition for administration to a patient suffering from at least one symptom of a cardiovascular condition, the composition comprising a) an...
8703143 Antibodies of the ED-B domain of fibronectin, their construction and uses  
According to the present invention there is provided a specific binding member which is specific for and binds directly to the ED-B oncofoetal domain of fibronectin (FN). The invention also...
8703125 Modulation of the Vps10p-domain receptor family for the treatment of mental and behavioural disorders  
The present invention relates to methods for modulating the activity of one or more Vps10p-domain receptors selected from the group consisting of Sortilin, SorLA, SorCS1, SorCS2 and SorCS3, in an...
8697071 Identification and engineering of antibodies with variant Fc regions and methods of using same  
The present invention relates to molecules comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which...
8697845 Antibodies specifically directed to a soluble form of CTLA-4  
The invention provides materials and methods relating to antibodies specific for a soluble form of CTLA-4 (sCLTA-4). Such antibodies have been shown to have a strong boosting effect on...
8697848 Method for reducing immunogenicity of therapeutic protein compositions  
The present invention provides methods for reducing and/or evaluating the immunogenic potential of a therapeutic protein preparation. The present invention further provides pharmaceutical...
8697068 Method for treating synovial sarcoma  
Methods of detecting synovial sarcoma using differentially expressed genes are disclosed. Also disclosed are methods of identifying agents for treating synovial sarcoma. Further, a method for...
8697133 Slow release compositions  
The present invention relates to the provision of micron or sub-micron sized particles formed from one or more water-soluble crystals comprising a surface coating comprising one or more bioactive...
8697069 Methods related to TIM 3, a Th1-specific cell surface molecule, for activating antigen presenting cells  
The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or...
8697070 1D05 PCSK9 antagonists  
Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present des...